A Phase 1 interventional study of rotigotine transdermal patch (Neupro®) in Healthy Volunteers, sponsored by UCB Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-27.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing sites.
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
Drug: rotigotine transdermal patch (Neupro®)
Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
Drug: rotigotine transdermal patch (Neupro®)
Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
Also known as: Neupro®
AUC(0-tz) of Unconjugated Rotigotine
The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Cmax of Unconjugated Rotigotine
The Cmax is the maximum plasma concentration.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
AUC(0-∞) of Unconjugated Rotigotine
The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine
The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
AUC(0-tz) Norm (BW) of Unconjugated Rotigotine
The AUC(0-tz) norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
AUC(0-∞) Norm (Apparent Dose)
The AUC(0-∞) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to infinity normalized by apparent dose (mg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
AUC(0-∞) Norm (BW)
The AUC(0-∞) norm (BW) is the area under the plasma concentration- time curve from zero up to infinity normalized by body weight (kg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine
The Cmax,norm (apparent dose) is the maximum plasma concentration normalized by apparent dose(mg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Cmax,Norm (BW) of Unconjugated Rotigotine
The Cmax,norm (BW) is the maximum plasma concentration normalized by body weight(kg).
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Tmax of Unconjugated Rotigotine
The tmax is the time to reach a maximum plasma concentration after patch application.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
MRT of Unconjugated Rotigotine
The MRT is the mean residence time.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
λz of Unconjugated Rotigotine
The λz is the rate constant of elimination.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
t1/2 of Unconjugated Rotigotine
The t1/2 is the terminal half- life.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
CL/f of Unconjugated Rotigotine
The CL/f is the apparent total body clearance.
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Apparent Dose
Apparent dose of unconjugated rotigotine in mg. The apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.
Time frame: 48 hours
A total of 40 healthy, male subjects has been randomized in order to complete the trial with at least 30 subjects eligible for the Pharmacokinetic Set (PKS). Baseline characteristics refer to the PKS.
| Milestone | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 19 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) |
|---|---|---|
| Started | 20 | 19 |
| Completed | 20 | 19 |
| Not completed | 0 | 0 |
| Milestone | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) |
|---|---|---|
| Started | 20 | 19 |
| Pharmacokinetic set (pks) | 20 | 18 |
| Completed | 20 | 19 |
| Not completed | 0 | 0 |
The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.
| (ng/ mL)*h | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-tz) of Unconjugated Rotigotine | 4.3899 ± 1.7959 | 4.4255 ± 2.3969 |
The Cmax is the maximum plasma concentration.
| ng/ mL | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Cmax of Unconjugated Rotigotine | 0.21103 ± 0.08827 | 0.20386 ± 0.10194 |
The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity
| (ng/ mL)*h | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-∞) of Unconjugated Rotigotine | 4.51237 ± 1.80709 | 4.55159 ± 2.42524 |
The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).
| (ng/ mL)*(h/ mg) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine | 2.23980 ± 0.71015 | 2.23035 ± 0.77992 |
The AUC(0-tz) norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).
| (ng/ mL)*h*kg | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-tz) Norm (BW) of Unconjugated Rotigotine | 364.930 ± 140.747 | 367.452 ± 189.279 |
The AUC(0-∞) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to infinity normalized by apparent dose (mg).
| (ng/ mL)*(h/ mg) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-∞) Norm (Apparent Dose) | 2.30523 ± 0.71105 | 2.29747 ± 0.78191 |
The AUC(0-∞) norm (BW) is the area under the plasma concentration- time curve from zero up to infinity normalized by body weight (kg).
| (ng/ mL)*h*kg | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| AUC(0-∞) Norm (BW) | 375.224 ± 141.465 | 378.003 ± 191.344 |
The Cmax,norm (apparent dose) is the maximum plasma concentration normalized by apparent dose(mg).
| (ng/ mL)/ mg | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine | 0.108148 ± 0.037618 | 0.103965 ± 0.035474 |
The Cmax,norm (BW) is the maximum plasma concentration normalized by body weight(kg).
| (ng/ mL) * kg | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Cmax,Norm (BW) of Unconjugated Rotigotine | 17.6070 ± 7.2645 | 16.9748 ± 8.1930 |
The tmax is the time to reach a maximum plasma concentration after patch application.
| hour (h) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Tmax of Unconjugated Rotigotine | 16.00 ± 4.92 | 16.00 ± 5.12 |
The MRT is the mean residence time.
| hour (h) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| MRT of Unconjugated Rotigotine | 19.914 ± 1.620 | 19.980 ± 2.038 |
The λz is the rate constant of elimination.
| 1/ hour (1/h) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| λz of Unconjugated Rotigotine | 0.129745 ± 0.026292 | 0.125217 ± 0.027732 |
The t1/2 is the terminal half- life.
| hour (h) | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| t1/2 of Unconjugated Rotigotine | 5.5408 ± 1.0205 | 5.7878 ± 1.1985 |
The CL/f is the apparent total body clearance.
| L/h | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| CL/f of Unconjugated Rotigotine | 1185.98 ± 574.45 | 1227.56 ± 541.82 |
Apparent dose of unconjugated rotigotine in mg. The apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.
| mg | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Apparent Dose | 1.932 ± 0.398 | 1.927 ± 0.489 |
Collected over Adverse Events (AEs) were collected up to 18 days from Day -1 (day before first dosing) to the Safety Follow- Up Visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A (Test: PR 2.1.1 WCL) | — | 0/39 (0%) | 5/39 (12.8%) |
| Treatment B (Reference: PR 2.1.1 AND) | — | 0/40 (0%) | 6/40 (15%) |
| Event | Treatment A (Test: PR 2.1.1 WCL) | Treatment B (Reference: PR 2.1.1 AND) |
|---|---|---|
| Application Site PruritusGeneral disorders | 4/39 | 3/40 |
| FatigueGeneral disorders | 1/39 | 0/40 |
| Hot FlushVascular disorders | 1/39 | 0/40 |
| NauseaGastrointestinal disorders | 0/39 | 1/40 |
| HeadacheNervous system disorders | 0/39 | 1/40 |
| Sleep DisorderPsychiatric disorders | 0/39 | 1/40 |
| Age, Continuous(years) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Mean | 37.0 ± 11.7 | 32.8 ± 7.2 | 35.0 ± 9.9 |
| Sex: Female, Male(Participants) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 20 | 18 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 20 | 18 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 20 | 18 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Mean | 25.03 ± 2.16 | 25.87 ± 1.77 | 25.43 ± 2.00 |
| Height(meter (m)) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Mean | 1.82 ± 0.07 | 1.82 ± 0.08 | 1.82 ± 0.08 |
| Weight(kilogram (kg)) | Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND) | Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL) | Total |
|---|---|---|---|
| Mean | 83.18 ± 9.62 | 85.33 ± 8.75 | 84.20 ± 9.16 |
The record gives a start of Jul 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine